📰 These Phase News
These Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from These Phase. Real-time updates on events, politics, business and more.
January 5, 2024
Merck today announced the launch of pivotal Phase 3 trials for four of its investigational drug candidates against hematological malignancies and solid tumors. These global studies involve: -...
March 27, 2023
Operator: Hello and welcome to the Moleculin Biotech Fiscal Year 2022 Quarterly Update Conference Call and Webcast. A question-and-answer session will follow the formal presentation.
December 10, 2022
- Phase 2 data demonstrate that the addition of parsaclisib to ruxolitinib (Jakafi®) resulted in spleen volume reduction and improvement in symptom burden in patients with myelofibrosis (MF) - Initial results of a Phase 1/2 study evaluating the safety and tolerability of INCB00928, an ALK2 inhibitor, show INCB00928 improves anemia in patients with MF both as monotherapy and in combination with ruxolitinib - These studies are part of our LIMBER program evaluating ruxolitinib combinations and ...
November 25, 2022
The Genshin Impact 3.3 release date, time, and 3.3 Banner and event schedule - featuring, Scaramouche, Faruzan, a new Archon Interlude quest, TCG, and events.
October 11, 2022
Dupixent (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old 68% of children
August 12, 2022
NY City, New York, United States, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Diamond in the Rough Click here for full length version of article. Allarity...
May 16, 2022
16.05.2022 - AV-101 is being developed to address cellular hyperproliferation and resistance to apoptosis in the pulmonary vasculature, which are key features of the pathophysiology of PAH PAH is an area of high unmet need, and currently approved therapies are ... Seite 1
October 15, 2021
Ad hoc announcement pursuant to Art. 53 LR Cash and cash equivalents of CHF 8.0 million (as of June 30, 2021)Net revenue CHF 4.5 million (H1-2020:...
October 15, 2021
Ad hoc announcement pursuant to Art. 53 LR Cash and cash equivalents of CHF 8.0 million (as of June 30, 2021)Net revenue CHF 4.5 million (H1-2020: CHF 7.8 million)Net result for period of CHF -20.5